ETF Building Blocks Channel Consolidation Could Come Calling for Biotech in 2022 By Tom LydonJanuary 5, 2022
Innovative ETFs Channel Moderna’s Omicron Booster Strategy Lifts Biotechnology ETFs By Max ChenNovember 29, 2021
ETF Building Blocks Channel Memeification of Biotech Stocks Shines Light on This ETF By Tom LydonNovember 24, 2021
Innovative ETFs Channel Pfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFs By Max ChenNovember 5, 2021
ETF Building Blocks Channel Biotech Ready to Participate in Healthcare Bullishness By Tom LydonOctober 29, 2021
ETF Building Blocks Channel Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Channel Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
ETF Prime ETF Prime: Tom Lydon Talks Pros & Cons of Market Cap Weighting By Aaron NeuwirthSeptember 1, 2021
Innovative ETFs Channel Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021